IgE Plasma Cell Leukemia Harboring t(11;14) and 1q Amplification
- PMID: 37408875
- PMCID: PMC10319461
- DOI: 10.1155/2023/4747989
IgE Plasma Cell Leukemia Harboring t(11;14) and 1q Amplification
Abstract
IgE plasma cell neoplasm is the rarest subtype of plasma cell neoplasms and is known for its poor prognosis and high incidence of t(11;14). However, t(11;14) has been classified as a standard-risk rather than high-risk cytogenetic abnormality in multiple myeloma. We have been unable to explain the discrepancy that the hallmark of IgE plasma cell neoplasm with a poor prognosis is a standard-risk cytogenetic abnormality. Here, we report a case of IgE primary plasma cell leukemia with extramedullary lesions of the liver, stomach, and lymph nodes. Plasma cell infiltration was pathologically confirmed in each organ. Cytogenetic analysis of plasma cells revealed t(11;14) and amplification of 1q21. Chemotherapy, with immunomodulatory imide drugs, proteasome inhibitors, and CD38 antibodies, was unsuccessful. In IgE plasma cell neoplasm, coexistence of other cytogenetic abnormalities with t(11;14) may be important. Investigating the presence of cytogenetic abnormalities coexisting with t(11;14) is not only useful for evaluating prognosis but also important for understanding the pathogenesis of the disease. Recently, venetoclax, an oral BCL2 inhibitor, has demonstrated promising efficacy in plasma cell neoplasm patients harboring t(11;14). Development of an effective venetoclax-based regimen for treating aggressive IgE plasma cell neoplasm with t(11;14) is expected.
Copyright © 2023 Wataru Nakahara et al.
Conflict of interest statement
The authors declare that they have no conflicts of interest.
Figures



Similar articles
-
Exploring the current molecular landscape and management of multiple myeloma patients with the t(11;14) translocation.Front Oncol. 2022 Aug 2;12:934008. doi: 10.3389/fonc.2022.934008. eCollection 2022. Front Oncol. 2022. PMID: 35982976 Free PMC article. Review.
-
Presentation and outcomes of patients with multiple myeloma harboring gain or amplification of 1q21 and receiving novel agent therapies: results from a single-center study.Hematology. 2023 Dec;28(1):2177979. doi: 10.1080/16078454.2023.2177979. Hematology. 2023. PMID: 36794720
-
Predictive value of 1q21 gain in multiple myeloma is strongly dependent on concurrent cytogenetic abnormalities and first-line treatment.Am J Cancer Res. 2021 Sep 15;11(9):4438-4454. eCollection 2021. Am J Cancer Res. 2021. PMID: 34659897 Free PMC article.
-
Observation on frequency & clinico-pathological significance of various cytogenetic risk groups in multiple myeloma: an experience from India.Indian J Med Res. 2016 Oct;144(4):536-543. doi: 10.4103/0971-5916.200890. Indian J Med Res. 2016. PMID: 28256461 Free PMC article.
-
Venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory multiple myeloma harboring t(11,14)(q13;q32): two case reports and a review of the literature.J Med Case Rep. 2020 Apr 23;14(1):54. doi: 10.1186/s13256-020-02376-y. J Med Case Rep. 2020. PMID: 32321588 Free PMC article. Review.
Cited by
-
Development of a Cytotoxic Antibody-Drug Conjugate Targeting Membrane Immunoglobulin E-Positive Cells.Int J Mol Sci. 2023 Oct 8;24(19):14997. doi: 10.3390/ijms241914997. Int J Mol Sci. 2023. PMID: 37834445 Free PMC article.
References
-
- Pandey S., Kyle R. A. Unusual myelomas: a review of IgD and IgE variants. Oncology . 2013;27(8):798–803. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials